Segment Reporting

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Segment Reporting

14.Segment Reporting

The Company views its operations and manages its business in one operating and one reportable segment, which includes all activities related to the identification, development and commercialization of medicines for childhood and adult diseases with equal intensity. The determination of a single operating segment is consistent with the consolidated financial information regularly provided to the Company’s chief operating decision maker, or CODM. The Company’s CODM is its Chief Executive Officer, who reviews and evaluates net loss for purposes of assessing performance, making operating decisions, allocating resources, and planning and forecasting for future periods. Our CODM does not evaluate the operating segment using asset or liability information. The operating segment derives all net product revenues from the sales of OJEMDA in the United States through contractual arrangements with its specialty pharmacy and specialty distributor customers. All the Company’s assets are located in the United States.

In addition to the significant expense categories included within net loss presented on the Company's condensed statements of operations, see below for disaggregated amounts that comprise research and development expenses:

	Three Months Ended June 30,				Six Months Ended June 30,
	2025		2024		2025		2024
					(in thousands)
External costs:
Third-party CRO, CMO and other third-party clinical trial costs (1)	$	22,087	$	22,547	$	42,908	$	42,093
License agreement related payments		—		55,000		4,000		60,000
Other research and development costs		2,001		2,346		4,021		4,513
Internal costs:
Employee related expenses		12,061		12,213		24,839		25,710
Total research and development expenses	$	36,149	$	92,106	$	75,768	$	132,316

(1) Costs incurred under agreements with third-party CROs, CMOs, and other third parties that conduct clinical activities on the Company's behalf.